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ABSTRACT 
The subcutaneous injection of insulin for the treatment of diabetes mellitus can lead to patient non-compliance, 
Diabetes discomfort, pain and local infection is a chronic metabolic health disease affecting the homeostasis of 
blood sugar levels in human beings. Oral route of drug delivery system has been the most widely accepted means 
of drug administration for formulating other than invasive drug delivery systems. For the development of an oral 
insulin delivery system, we have to focus on defeating various gastro-intestinal barriers for insulin uptake across 
the gastrointestinal tract. To defeat these barriers various types of formulations such as insulin conjugates, 
micro/nanoparticles, liposomes, hydrogel, capsule, and tablets are designed to deliver insulin orally. Various 
potential ways to administer insulin orally has been explored over years but a fluctuating level of success. A 
number of advancement has taken place in the recent years for understanding the needs of improved oral delivery 
systems of insulin. This review article concentrates on the challenges for oral drug delivery of insulin as well as 
various carriers used for the oral drug delivery of insulin and also provides the relevant information about the 
clinical tested formulations of oral insulin and its patents. 
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INTRODUCTION 
The effective treatment of diabetic person with insulin need painful route of administration. Although invasive 
routes are poorly acceptable by the diabetics but other noninvasive routes of administrations are highly expedient
1
. 
Administration of drugs by oral route is the most acceptable route of administration, but it is difficult to deliver 
peptide and protein drugs by this route. Presystemic enzymatic degradation and poor penetration of the intestinal 
membrane are the main reasons for the low oral bioavailability of peptide and protein drugs
2
. Oral bioavailability 
of insulin is below 1% so there is a big challenge to improve it upto 30%–50%3. A number of polymers both 
biodegradable and non-biodegradablepolymers have been studied for non-invasive delivery of insulin. Non-
biodegradable polymers possess problems of toxicity, difficulty in eviction and also sustained release of insulin 
cannot be attained using these polymers. Biodegradable polymers favour the uptake of insulin through intestinal 
cells by shielding the encapsulated drug from the external harsh conditions. Biodegradable polymeric particles 
protect the peptide from the peptidases, so that they can be uptake by enterocytes. Polymeric particles will slowly 
degrade after absorption depending on the nature of the polymer; provide a sustained and controlled release of the 
drug
4
.Various strategies have to be implemented to maximize oral insulin bioavailability to defeat GI barriers, and 
to bring safe and effective oral dosage form to the market
5
. In order to attain an ideal oral peptide drug delivery 
system, some alternates will be required to encapsulate the insulin
6
.For the oral delivery of peptide and protein 
drugs, nanocarriers have shown great potential withimproved pharmacokinetics and pharmacodynamics of insulin. 
Nanocarriers or nanoparticlescan stabilize these macromolecular drugs by providing insulation from the harsh GI 
conditions and accelerating their transport across the absorptive epithelia
7
. The new strategies for products that are 
tried before include water-soluble, long-acting insulin derivative, [(2-Sulfo)-9-fluorenylmethoxycarbonyl]3-insulin, 
vitamin B12-dextran nano particles, lipid nano particles and PEGylated calcium phosphate nanoparticles etc  as 
oral drug delivery carriers for insulin
8
.  
 
 VARIOUS CHALLENGES TO ORAL INSULIN DRUG DELIVERY 
Absorption across GIT membrane 
General route for absorption of drug molecules is the Paracellular and the transcellular route. Hydrophilic 
molecules having mol. Wt. less than 500 Da absorbed by Paracellular route. The molecules having high molecular 
weight like insulin (about 6KDa) cannot absorb via this route. Absorption of insulin by transcellular route is 
restricted because of its molecular size, its charge, and its hydrophilicity
9
. To increase the GI uptake of orally 
poorly absorbed insulin is their binding to colloidal particles that can safeguard the insulin from degradation in the 
GI tract and encourage the transport of poor-absorbable molecules into systemic circulation
10
. 
Presystemic enzymatic degradation 
Pepsin is present inside the stomach as a group of aspartic proteases. Pancreatic proteases existing in small 
intestine comprising the serine endopeptidase (trypsin, α-chymotrypsin, elastase and exopeptidases, 
carboxypeptidase A, and carboxypeptidase B) which is accountable for the degradation of proteins.The order of 
enzymatic degradation of insulin in the small intestineis Duodenum> jejunum > ileum
9
.Insulin can be available for 
absorption through GIT when the enzymatic attack is either diminished or defeated
11
.Although Insulin is not 
subject to proteolytic breakdown by brush border enzymes
12
. 
Poor Intestinal transport of insulin 
The anatomy of insulin is very exquisite. Insulin is susceptible to oxidative damage when react amino acids
9
. In 
other terms we can say that insulin has low permeability via intestinal mucosa
11
. 
Dosage form stability 
Proteins changesits conformation, size, shape, surface properties, and bioactivity upon development into different 
formulations. Changes in conformation, size, shape can be detected by use of spectrophotometric techniques, X-ray 
diffraction, differential scanning calorimetery, light scattering, electrophoresis, and gel filtration
12
.(Figure 1) 
FEATURES OF AN ABSOLUTEORAL INSULIN CARRIER 
An absolute carrier for insulin: 
■ should be pH sensitive. 
■ should provide a biocompatible and stable environment to ensure that the active part of insulin will remain 
biologically active after encapsulation. 
■ should reduce or avoid enzyme degradation and increase insulin permeability across the intestinal membrane. 
■ thepermeability of the mucosal epithelium to enhance the absorption ofinsulin and provide the intact insulin to 
the blood circulation. 
■ must be safe after oral administration. 
■ Insulin should be available for interaction with cell surface receptors and captured by lymphatic cells, or pass 
through or be entrapped in thelymph nodes or transferred to the systemic circulation, provided that the particles 
remain as such and particle size will be acceptable up to a limit
13
. 
DIVERSE CARRIERS USED FOR NON INVASIVE DRUG DELIVERY OF INSULIN  
Insulin-loaded Bioadhesive PLGA Nanoparticles for Oral Drug Delivery 
PEGylation play an important role in increasing the stability of several therapeutic proteins
14
.For the drug delivery 
system of proteins and peptides Poly (D, L-lactide-co-glycolide) nanoparticles (PLGA-NP) have been used 
extensively. Chitosan PLGA nanoparticle hassome attractive properties, such as a mucosal adhesion, positive 
charge, and absorption enhancement, which increase the duration of residence of insulin in in-vitro and improve its 
bioavailability in in-vivo for oral delivery
15
.The negative surface charge present on PLGA nanoparticles tends to 
reduce the oral bioavailability bylimiting the diffusion of insulin nanoparticle across the mucus layer. Cationic 
chitosan can be used tocoat and modify the surface charge of PLGA nanoparticles
16
. 
Polymeric Hydrogels for Oral Insulin Delivery 
 Nature of the polymer might enhance the residence time of a drug delivery system inside the GI 
tract
17
.Polymerichydrogels protect insulin from enzymatic degradation in acidic environment of stomach and 
deliversinsulin effectively in the intestinal region. Swelling andde-swelling mechanisms of the hydrogel under 
differentpH conditions of the body control the release of insulin. A Combination of enzyme inhibitors and 
polymeric systems have potentialto increase the potency of orally given insulin
15
.  
Acrylic Polymers for Oral Insulin Delivery 
Acrylic polymers are synthetic mucoadhesive polymers, basically intended for oral drug delivery. Various 
technique used to generate Synthetic polymers areNano precipitation, solvent evaporation, freeze–drying, spray 
drying of emulsions and supercritical fluid technology
15
. Methacrylic acid or acrylic acid are used as copolymerfor 
their pH-sensitive nature and ability to bind calcium, and poly (ethylene glycol) because of its ability to stabilize 
and protect proteins
18
. 
Aerosolized Liposomes for Pulmonary Delivery of Insulin 
Pulmonary route for systemic delivery of peptides and proteins is paid more attention because it’s a non-invasive 
method of administrating insulin and hence valuable for the delivery of large molecular proteins
14
.This method is 
effective for both type 1(T1DM) and type 2 diabetes mellitus(T2DM)
19
. Generally lungs have large surface area 
(approximate about 100 square metres) and acts as an ideal target for insulin delivery
20
. 
Chitosan–zinc–insulin Complex  
Chitosan, a biodegradable polymer and a cationic polysaccharide, has been extensively known for the preparation 
of nanoparticles for oral controlled delivery. Chitosan derivatization of  polymers that improve drug retention 
capability, provideimproved permeation, enhanced mucoadhesion and sustained release of therapeutic agents
8
. 
MARKET STATUS OF ORAL INSULIN FORMULATIONS 
In the recent years, the oral dosage form development of insulin is at different clinical stages frompre-clinical 
testing to Phase II clinical trials
21
. Oralin has been successfully trailed in Type 1 and Type 2 diabetic patients and 
when the results were compare with subcutaneous injectionit was find appropriate for controlling blood glucose 
level
22
. A remarkable progress has been reported in the recent past years for the delivery of insulin by non-invasive 
routes. Some of other hormonal drugs, such as calcitonin and vasopressin, are available in the form of intranasal 
sprays. The field of oral insulin delivery took an enormous step ahead with the approval of Exubera® from Pfizer 
and Nektar Therapeutics
5
.(Table 1) 
CONCLUSION 
An extensive number of peopleespecially in developed countries are suffered from diabetes. The pharmacotherapy 
for T1DM and T2DM treatment is subcutaneous injection of insulin. Discomfort, pain and local infection are 
themain reasons for patient non-compliance. On the otherhand, if we develop oral dosage form of insulin 
formulation then we can improve patient acceptability. Painful administration and phobia from invasive routes 
have couragescientists to research new possible methods for oral insulin delivery. 
Various barriers to insulin uptake by oral routes has its own set of advantages and disadvantages. Over the last few 
years, researchers have focused on oral insulin delivery. Although extensive human clinical studies are still the 
major requirement of oral insulin drug delivery and for theoptimisation of physiochemical and pharmacokinetic 
parameters of insulin as drug carrier for diabetes treatment. 
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Figure 1. Various challenges to oral insulin drug delivery 
 
Table 1. List of clinically tested oral insulin formulation
9
. 
Company  Name  Product  Development 
phase 
Biocon/Bristol-Myers Squibb IN-105 Conjugate Insulin  II 
Access Pharmaceuticals, Inc CobOral™ Insulin coated insulin-loaded nanoparticles II 
Aphios Corporation APH-0907 Nanoencapsulated insulin/ biodegradable 
polymer nanospheres 
PRECLINICAL 
Diabetology Ltd Capsulin™ 
OAD 
Insulin with delivery system Axcess™ II 
Diasome Pharmaceuticals, Inc. HDV-Insulin Hepatic-directed vesicle-insulin (nanocarrier) III 
Emisphere Technologies, Inc. Eligen® 
insulin 
Insulin with chemical delivery agents 
(Eligen®) 
I 
Jordanian Pharmaceutical 
Manufacturing Co. PLC 
JPM oral Liquid delivery system with insulin-chitosan 
nanoparticles 
I 
Novo Nordisk A/S NN1952 Insulin analog with an oral delivery system 
GIPET® 
 
Oramed, Inc. ORMD-0801 Insulin with protein oral delivery system 
POD™ 
II 
Oshadi Drug Administration 
Ltd 
Oshadi Icp. Insulin, proinsulin, and C-peptide in Oshadi 
carrier 
II 
NOD Pharmaceuticals, Inc./ 
Shanghai Biolaxy, Inc. 
Nodlin Insulin with bioadhesive nanoencapsulation 
(NOD Tech) 
II 
Transgene Biotek Ltd. TBL1002OI Proprietary nanotechnology Trabi-Oral™ PRECLINICAL 
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